. 2018 Jun 15;10(6):1908–1920.

Table 1.

The relationship between GPX3 methylation and clinicopathological features in ESCC patients

Clinical data	Number	GPX3 methylation status		Positive rate (%)	X²	P

		Positive	Negative
Gender
Male	13	12	1	0.923	0.167	0.683
Female	11	10	1	0.909	0.167	0.683
Age (year)
<60	8	7	1	0.727	2.667	0.102
≥60	16	15	1	0.938	2.667	0.102
Family history
Yes	8	8	0	1	0.167	0.683
No	16	14	2	0.875	0.167	0.683
Tumor size
<5	11	10	1	0.909	0.167	0.683
≥5	13	10	3	0.769	0.167	0.683
T-stage
T1-2	10	9	1	0.9	0.667	0.414
T3	14	13	1	0.929	0.667	0.414
N-stage
N0-1	21	19	2	0.905	13.5	0.0001^*
N2	3	3	0	1	13.5	0.0001^*
Tumor-stage
I-II	18	17	1	0.944	6	0.014^*
III	6	6	0	1	6	0.014^*

significant difference.